Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
Resumen:
Aberrant glycosylation is a common feature of many cancers, and it plays crucial roles in tumor development and biology. Cancer progression can be regulated by several physiopathological processes controlled by glycosylation, such as cell–cell adhesion, cell–matrix interaction, epithelial-to-mesenchymal transition, tumor proliferation, invasion, and metastasis. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs), which are suitable for selective cancer targeting, as well as novel antitumor immunotherapy approaches. This review summarizes the strategies developed in cancer immunotherapy targeting TACAs, analyzing molecular and cellular mechanisms and state-of-the-art methods in clinical oncology.
| 2022 | |
|
Tumor glycans Cancer immunotherapy Cancer glycobiology Monoclonal antibodies Cancer vaccines CAR-T cells NEOPLASIAS POLISACÁRIDOS GLYCOBIOLOGÍA INMUNOTERAPIA ADOPTIVA VACUNAS CONTRA EL CÁNCER LINFOCITOS T |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/55230 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución (CC - By 4.0) |
